One target — independent paths to value creation.
Programs span neurodevelopmental, neurodegenerative, and acute indications. Click any row for current status, key readouts, and partners.
Injury-modifying program targeting AVP-V1a–driven secondary injury cascade following mild traumatic brain injury. In a translational momentum-exchange mTBI model, SRX251 and AVN849 reduced neuronal injury biomarkers, prevented cognitive deficits on Novel Object Recognition test (treatment 15 min and 6 hrs post-injury).
- Key readouts & milestones
- Translational single and repetitive TBI preclincial model: Treatment shortly after insult reduced neuronal injury; eliminated cognitive deficits; restored circadian activity.
Department of Defense–funded Phase 2 trial of SRX246 for anxiety and aggression in Fragile X Syndrome. Double-blind crossover design with home visits enables participation by individuals previously excluded from clinical trial participation. Genetically defined disorder with severe aggression and anxiety; gateway to autism spectrum disorder expansion.
- Key readouts & milestones
- Interim data Q3 2027; complete Q3 2028. Orphan designation in process.
- Partners / collaborators
- Rush University, UC Cincinnati Children's Hospital, UC Davis
A first-in-class V1a receptor antagonist for the treatment of problematic aggression in Huntington's Disease. Phase 2 trial across 22 sites met primary, secondary, and exploratory endpoints with clinical benefit and a clean safety/tolerability profile.
- Key readouts & milestones
- Orphan Drug Designation; Fast Track Designation; FDA agreement on pivotal trial design and endpoints.
- Partners / collaborators
- NINDS NeuroNext
Phase 2 clinical trial of SRX246 for the treatment of Intermittent Explosive Disorder. Results showed excellent tolerability and safety, with reductions in severe aggressive episodes and lessened disability due to the disorder.
- Key readouts & milestones
- Reduction in severe aggression episodes; decrease in aggression-related disability days.
Clinical milestones & value inflection.
Funded clinical progression with additional programs positioned for advancement.
Funded mid-stage program with paired data readouts.
DoD-funded study with double-blind crossover design and home-visit participation, conducted across three sites: Rush University, Cincinnati Children's Hospital, and UC Davis. Two readout windows positioned for capital and partnering decisions:
- Q3 2027 — interim readout
- Q3 2028 — complete data
Orphan Drug Designation in process.
Program detail →
Phase 3-ready asset with FDA-aligned design.
Pivotal trials with capital availability. FDA agreement on pivotal trial design and endpoints. Orphan and Fast Track designations support an efficient registration path.
Program detail →
IND-enabling in progress; Phase 2a injury-modifying study planned.
Translational mTBI evidence with SRX251 and AVN849 — reduced euronal damage and preserved cognition in concusse, untreated comparators. Phase 2a trial with capital; non-US sites under evaluation.
Program detail →
$56M raised across venture and non-dilutive sources.
Lead investors
Ascent Biomedical Ventures · Scientific Health Development
NIH programs
SBIR · RAID · NeuroNext · National Toxicology Evaluation Program
Use of proceeds
Fragile X follow-on · HD registration trials · mild TBI to Phase 2a go/no-go
10 U.S. patents and 50+ foreign patents.
New uses for Azevan's V1a antagonists, with 5-year extensions under U.S. Hatch-Waxman and EP Supplementary Protection Certificate.
Investor & partnership inquiries.
For additional information about partnership, investment, or our pipeline programs:
Neal G. Simon, Ph.D. — Chief Executive Officer
ngsimon@azevan.com · 610-509-6127